FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average	burden						
nours per response	e 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person * Kim Mina				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							l	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900			3. Date of Earliest Transaction (Month/Day/Year) 03/26/2019							ar)	X Officer (give title below) Other (specify below) Senior VP & General Counsel						
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City		(State)	(Zip)		Table I - Non-Derivative Securities Acqui							ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	Execu	Deemed ation Date.	, if (. Transa Code Instr. 8)	v	4. Secu (A) or (Instr.	Dispo	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		following (s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock 03/26/2019			A			10,000 A \$ 0		\$ 0	70,063			D					
reminder.	report on a s	separate fine re	or each class of secur	Deriva	tive Secui	rities	Acquire	Perso conta the fo	ons whained it orm dis	no re n thi splay	s for ys a	m are curre eficial	not requesting ntly valid	OMB cont	ormation spond unle trol numbe	ss	1474 (9-02)
1. Title of	2	3. Transaction		`	uts, calls,	warr 5.	ants, op		conver te Exer				itle and	8 Price of	9. Number	of 10.	11. Natur
	Conversion or Exercise Price of Derivative Security	e (Month/Day/Ye	Execution Da	ite, if	Γransactio Code	on Numof De See Ac (A Disof (In	Number		and Expiration Date (Month/Day/Year)			Amo Und Secu	ount of lerlying urities tr. 3 and		Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Security Direct (or Indir	of Indirect Beneficia Ownershi (Instr. 4)
				Code	Code V	/ (A	(D)	Date Exerc		Expi Date	iration	1 Title	Amount or Number of Shares				

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Kim Mina C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080			Senior VP & General Counsel					

Signatures

/s/ David Tucker, Attorney-in-Fact for Mina Kim	03/27/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.